Telephone-Based Intervention in Increasing Adherence to Adjuvant Hormonal Therapy in Patients With Breast Cancer
Recruiting
This pilot trial studies a telephone-based intervention to see if it increases adherence to adjuvant hormonal therapy in patients with breast cancer. Increasing communication between doctors and patients with breast cancer may help patients to better follow recommendations on taking adjuvant hormonal treatment medication. A telephone-based intervention may help to increase doctor-patient communication and patients' adherence to their prescribed medication.
Gender:
Female
Ages:
18 years and above
Trial Updated:
10/27/2022
Locations: Fletcher Allen Health Care-Medical Center, Burlington, Vermont
Conditions: Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage 0 Breast Cancer
Connect® Myeloid Disease Registry
Recruiting
The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. This disease registry will also evaluate molecular and cellular markers that may provide further prognostic classification which may or may not be predictive of therapy and clinical outcomes.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/25/2022
Locations: Foley Cancer Center/RRMC, Rutland, Vermont
Conditions: Myelodysplastic Syndromes, Primary Myelofibrosis, Leukemia, Myeloid, Acute
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
Recruiting
Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior induction regimens: Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion at a dose of 6 mg/m²/day followed by a 14-day resting period per 28-day cycles. Control arm: Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens), dependin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/18/2022
Locations: University of Vermont Medical Center, Burlington, Vermont
Conditions: Leukemia, Myeloid, Acute
A Prospective Pilot Study of a Non-Narcotic Post-Operative Course After Colectomy
Recruiting
With this pilot investigation, the investigators aim to challenge the reliance on opiate analgesia following colon and rectal surgery. Narcotic misuse and abuse is a pressing public health concern, and reduction in prescription rates could help to mitigate this issue. The goal of this pilot study is to establish feasibility of sufficient post-operative pain control after colectomy using non-narcotic analgesics. The investigators hypothesize that patients will be able to manage their post-operati... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/13/2022
Locations: UVM Medical Center, Burlington, Vermont
Conditions: Analgesia, Post-Operative Pain, Breakthrough Pain, Colectomy
Prolonged Exposure Therapy for PTSD and Opioid Use Disorder
Recruiting
Among patients with opioid use disorder (OUD), 90% report lifetime trauma exposure and 33% meet criteria for posttraumatic stress disorder (PTSD). The co-occurrence of OUD and PTSD is associated with worse mental health and opioid agonist treatment (OAT) outcomes relative to either diagnosis alone. Prolonged exposure therapy (PET) is an efficacious cognitive-behavioral treatment for reducing PTSD severity. Although preliminary findings indicate that PET may reduce PTSD symptom severity among pat... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/04/2022
Locations: University of Vemont, Burlington, Vermont
Conditions: Post Traumatic Stress Disorder, Opioid-use Disorder
CxBladder Surveillance of Intermediate and High-Risk Bladder Cancer Patients
Recruiting
Surveillance for recurrence of urothelial carcinoma (UC) requires frequent cystoscopy, which is invasive, expensive and time-consuming. An accurate urinary biomarker has the potential to reduce the number of cystoscopies required during post-treatment surveillance. This is a prospective single arm multi-center study using the diagnostic CxBladder test with subjects previously diagnosed positive with primary or recurrent UC and who are undergoing a schedule of investigative cystoscopies and treat... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/12/2022
Locations: White River Junction Veterans Affair Medical Center, White River Junction, Vermont
Conditions: Urothelial Bladder Cancer
USCRI Ready4Life Program
Recruiting
The U.S. Committee for Refugees and Immigrants (USCRI) has developed the Relationships, Education, Advancement, and Development for Youth for Life (READY4Life) Program. This is a 16-hour program for immigrants/refugees, ages 14 to 24. The program is designed to help young immigrants and refugees prepare for a successful life in the United States. The program is taught by USCRI program staff and is being implemented at eight sites across the U.S.: Cleveland, Ohio; Colchester, Vermont; Des Moines,... Read More
Gender:
All
Ages:
Between 14 years and 18 years
Trial Updated:
07/25/2022
Locations: USCRI Vermont, Colchester, Vermont
Conditions: Communication, Problem Solving, Social Relationships, Economic Stability
Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
Recruiting
This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer in response to treatment (complete response) or a decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment (partial response). Immunotherapy with obinutuzumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to gro... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/09/2022
Locations: University of Vermont Medical Center, Burlington, Vermont
Conditions: Central Nervous System B-Cell Non-Hodgkin Lymphoma
Intratumoral Cisplatin for Resectable NSCLC
Recruiting
PRIMARY OBJECTIVE: To identify the maximum tolerated dose (MTD) of intratumoral cisplatin, delivered during a single bronchoscopy with cone-beam CT confirmation, in a dose escalation protocol DESIGN: 3+3 dose escalation.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2022
Locations: University of Vermont, Burlington, Vermont
Conditions: Non-Small Cell Lung Cancer
Phase 1 Trial of Endobronchial Ultrasound-Guided Transbronchial Needle Injection of Cisplatin for Stage IV Lung Cancer
Recruiting
The goal of the study is to identify the maximum tolerated dose of endobronchial ultrasound-guided transbronchial injection (EBUS-TBNI) of cisplatin for Stage IV lung cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2022
Locations: University of Vermont, Burlington, Vermont
Conditions: Lung Cancer Metastatic
NMES in HF Patients to Improve Functional Recovery Following Hospitalization
Recruiting
The goal of this research study is to understand whether an at-home exercise program started after hospitalization for HFpEF, and continuing for 4 weeks following discharge from the hospital, can preserve or improve physical function.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
04/13/2022
Locations: University of Vermont Medical Center, Burlington, Vermont
Conditions: Heart Failure With Preserved Ejection Fraction
The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes
Recruiting
The objective of this study is to collect both active and passive data using a wearable, multi-sensor device (Verily Study Watch) and phone application (Mood App) which aims to capture mental health status, in subjects participating in the RECOVER clinical trial (A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/23/2022
Locations: Neuropsychiatric Associates, Plc, Woodstock, Vermont
Conditions: Treatment Resistant Depression